Table 1.

Univariate and multiple Cox-regression models

A
Training cohort; GPhL scoreUnivariateMultiple
N = 65; 29 eventsHR (CI95%)PHR (CI95%)P
Age (decades)1.99 (1.36–2.94)<0.0012.91 (1.86–4.57)<0.001
FIGO (IV vs. III)1.09 (0.41–2.88)0.866-1-
Grade (3 vs. 2)1.05 (0.42–2.59)0.920-1-
Residual tumor (yes vs. no)1.61 (0.76–3.40)0.216-1-
ECOG status (1/2/3 vs. 0)2.94 (0.96–8.98)0.058-1-
 Ascites (>500 vs. ≤500 vs. 0)21.59 (0.98–2.58)0.059-1-
LDL20.61 (0.31–1.21)0.1590.14 (0.04–0.49)0.002
GPhL score (high vs. medium vs. low)0.44 (0.27–0.72)0.0010.46 (0.26–0.81)0.007
B
Validation cohort; Gene predictorUnivariateMultiple
N = 165; 78 eventsHR (CI95%)PHR (CI95%)P
Age (decades)1.43 (1.16–1.75)<0.0011.48 (1.19–1.85)<0.001
FIGO (IV vs. III)2.51 (1.56–4.04)<0.0012.33 (1.42–3.82)<0.001
Grade (3 vs. 2)2.12 (1.18–3.79)0.0112.04 (1.12–3.74)0.021
Residual tumor (yes vs. no)1.76 (1.11–2.79)0.0171.79 (1.12–2.88)0.015
Gene predictor (high vs. medium vs. low)0.83 (0.63–1.09)0.1800.65 (0.50–0.88)0.004
  • NOTE: A, Cox-regression analyses of the training cohort, using the trichotomized GPhL score. B, Cox-regression analyses of the validation cohort, using the trichotomized gene predictor, comprised of 100-gene expression values.

  • 1Excluded from the model by the backward elimination procedure maximizing the AIC.

  • 2Replaced separately by BMI, CA125, CRP, fibrinogen, albumin, HDL, cholesterol, triglycerides, ascites, and an AA score, comprising the five significant OS-associated AAs.